Nuvalent, Inc. (NUVL) Thursday reported a wider net loss for the first quarter compared to the prior year.
The Cambridge, Massachusetts-based clinical-stage biopharmaceutical company reported loss of $44.48 million for the first quarter, compared to $25.19 million in the previous year.
On a per-share basis, loss was $0.69 per share, wider than $0.44 last year.
On average, 9 analysts polled by Thomson Reuters expected the company to report loss of $0.68 per share. Analysts estimates usually exclude special items.
James Porter, CEO of Nuvalent said, "We expect to share clinical updates from our parallel lead programs for ROS1-positive and ALK-positive NSCLC at a medical meeting in the second half of the year and are on-track to dose the first patient in our HER2 program this year."
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.